All In Biotech

NDA 205703 · Hq Spclt Pharma

Esmolol Hydrochloride Double Strength In Plastic Container

Esmolol Hydrochloride · Intravenous

Last checked: Nov 19, 2026Latest source record: May 2, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Apr 7, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

99

17 Phase 3, 7 recruiting

FAERS reports

115

104 serious, 17 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 31, 2024.

Esmolol Hydrochloride is a beta-adrenergic blocker indicated for the short-term treatment of: • Control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia ( 1.1 ) • Control of perioperative tachycardia and hypertension ( 1.2 ) 1.1 Supraventricular Tachycardia or Noncompensatory Sinus Tachycardia Esmolol hydrochloride is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short-term control of ventricular rate is desirable. Esmolol hydrochloride is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. Esmolol hydrochloride is intended for short-term use. 1.2 Intraoperative and Postoperative Tachycardia and Hypertension Esmolol hydrochloride is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated. Use of esmolol hydrochloride to prevent such events is not recommended.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER · ESMOLOL HYDROCHLORIDE 2GM/100ML (20MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER · ESMOLOL HYDROCHLORIDE 2.5GM/250ML (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Esmolol" as an intervention, any sponsor and status, largest first.

All 99 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective22
  • product use issue15
  • product use in unapproved indication12
  • cardiac arrest7
  • condition aggravated6
  • drug ineffective for unapproved indication6
  • hepatotoxicity6
  • hyperbilirubinaemia6
  • hypotension6
  • cardiogenic shock5
  • hepatomegaly5
  • hypertension5

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20091
20123
20132
20142
20152
20161
20174
20187
201912
20205
202113
20229
202318
20247
202522
20267

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 395 on PubMed

Sponsor: Hq Spclt Pharma · Also marketed as Esmolol Hydrochloride In Plastic Container

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.